These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1455904)

  • 21. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.
    Sathyan G; Chancellor MB; Gupta SK
    Br J Clin Pharmacol; 2001 Oct; 52(4):409-17. PubMed ID: 11678784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The measurement of d-fenfluramine and its metabolite, d-norfenfluramine in plasma and urine with an application of the method to pharmacokinetic studies.
    Richards RP; Gordon BH; Ings RM; Campbell DB; King LJ
    Xenobiotica; 1989 May; 19(5):547-53. PubMed ID: 2750211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pharmacokinetics of oxybutynin in man.
    Douchamps J; Derenne F; Stockis A; Gangji D; Juvent M; Herchuelz A
    Eur J Clin Pharmacol; 1988; 35(5):515-20. PubMed ID: 3234461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids.
    Lukkari E; Hakonen T; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Jan; 53(5):351-4. PubMed ID: 9516036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite.
    Lukkari E; Juhakoski A; Aranko K; Neuvonen PJ
    Eur J Clin Pharmacol; 1997; 52(5):403-6. PubMed ID: 9272412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimuscarinic activity of oxybutynin in the human plasma quantitated by a radioreceptor assay.
    Aaltonen L; Allonen H; Iisalo E; Juhakoski A; Kleimola T; Sellman R
    Acta Pharmacol Toxicol (Copenh); 1984 Aug; 55(2):100-3. PubMed ID: 6496110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics/pharmacodynamics analysis of the relationship between the in vivo micturition pressure and receptor occupancy of (R)-oxybutynin and its metabolite in rats.
    Mizushima H; Kinoshita K; Abe K; Ishizuka H; Yamada Y
    Biol Pharm Bull; 2007 May; 30(5):955-62. PubMed ID: 17473442
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet.
    Lukkari E; Aranko K; Juhakoski A; Hakonen T; Neuvonen PJ
    Pharmacol Toxicol; 1997 Jul; 81(1):31-4. PubMed ID: 9258982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between plasma propranolol concentration and dose in young, healthy volunteers.
    Dey M; Brisson J; Davis G; Enever R; Pray K; Zaim B; Dvornik D
    Biopharm Drug Dispos; 1986; 7(2):103-11. PubMed ID: 3708118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-performance liquid chromatographic method for the determination of a cyclandelate metabolite, mandelic acid, in human plasma.
    Kojima K; Uezono Y; Takahashi T; Nakanishi Y
    J Chromatogr; 1988 Mar; 425(1):203-7. PubMed ID: 3360871
    [No Abstract]   [Full Text] [Related]  

  • 31. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide.
    Wynne HA; Yelland C; Cope LH; Boddy A; Woodhouse KW; Bateman DN
    Age Ageing; 1993 Sep; 22(5):354-9. PubMed ID: 8237626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma aspirin esterase: the influence of old age and frailty.
    Williams FM; Wynne H; Woodhouse KW; Rawlins MD
    Age Ageing; 1989 Jan; 18(1):39-42. PubMed ID: 2496585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of plasma concentrations of cyclandelate and mandelic acid in patients with generalized atherosclerotic vasculopathy treated with oral cyclandelate.
    Forconi S; Cappelli R; Guerrini M; Volpi L; Frigerio C; Di Perri T
    J Int Med Res; 1990; 18(4):266-72. PubMed ID: 2227073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The kinetics of plasma aspirin esterase in relation to old age and frailty.
    Summerbell J; Yelland C; Woodhouse K
    Age Ageing; 1990 Mar; 19(2):128-30. PubMed ID: 2337009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).
    Shah RR
    Br J Clin Pharmacol; 2004 Nov; 58(5):452-69. PubMed ID: 15521892
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetic and Pharmacodynamic Changes in the Elderly: Impact on Anesthetics.
    Coetzee E; Absalom AR
    Anesthesiol Clin; 2023 Sep; 41(3):549-565. PubMed ID: 37516494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bleeding under pressure.
    Man CB; Ghai NE; Branford OA; Dickson MG
    J Plast Reconstr Aesthet Surg; 2010 Mar; 63(3):e334-5. PubMed ID: 19628442
    [No Abstract]   [Full Text] [Related]  

  • 38. So frail and fleeting a thing is man.
    Aronson SM
    Med Health R I; 2011 Jun; 94(6):151. PubMed ID: 21748980
    [No Abstract]   [Full Text] [Related]  

  • 39. Home blood pressure measurement in the frail elderly: does it matter?
    Bursztyn M; Grassi G
    J Hypertens; 2017 Dec; 35(12):2374-2376. PubMed ID: 29095230
    [No Abstract]   [Full Text] [Related]  

  • 40. Initial Hodgkin treatment of the frail elderly.
    Straus DJ
    Blood; 2017 Dec; 130(26):2813-2814. PubMed ID: 29284610
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.